{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:10:03Z","timestamp":1787065803525,"version":"build-2736575974"},"reference-count":27,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: In Uganda, national tuberculosis (TB) treatment guidelines were revised to include the newer generation fluoroquinolones among the second-line treatment options for multidrug-resistant TB. This study was designed to analyze if the prescription of these quinolones is compliant with country recommendations. Methods: This was an observational retrospective study of consumption data for 2017 and 2018 across four selected regional referral hospitals. The sources of consumption data were hospital pharmacy stock cards and the dispensing register. The medical files of patients who had been prescribed fluoroquinolones were also assessed to study compliance with the Uganda Clinical Guidelines and the British National Formulary (BNF). Results: None of the 371 levofloxacin prescriptions analyzed complied with the Uganda Clinical Guidelines, although 250 (67.3%) were prescribed for indications included in the BNF. According to WHO prescription indicators, only 220 (59.3%) prescriptions were appropriate. Conclusion: The prescription of levofloxacin and moxifloxacin increased in the hospitals studied, but in a high proportion of cases, they were not compliant with country recommendations. The findings call for the strengthening of national antimicrobial stewardship programs.<\/jats:p>","DOI":"10.3390\/antibiotics9080439","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T10:14:06Z","timestamp":1595499246000},"page":"439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prescription of Levofloxacin and Moxifloxacin in Select Hospitals in Uganda: A Pilot Study to Assess Guideline Concordance"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7961-9687","authenticated-orcid":false,"given":"Victoria","family":"Nambasa","sequence":"first","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority (NDA), Kampala 23096, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-4791","authenticated-orcid":false,"given":"Helen B.","family":"Ndagije","sequence":"additional","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority (NDA), Kampala 23096, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Serwanga","sequence":"additional","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority (NDA), Kampala 23096, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Manirakiza","sequence":"additional","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority (NDA), Kampala 23096, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanitah","family":"Atuhaire","sequence":"additional","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority (NDA), Kampala 23096, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Nakitto","sequence":"additional","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority (NDA), Kampala 23096, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Kiguba","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Makerere University College of Health Sciences, Kampala 7072, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2013","authenticated-orcid":false,"given":"Albert","family":"Figueras","sequence":"additional","affiliation":[{"name":"Departament de Farmacologia, Terap\u00e8utica i Toxicologia, Universitat Aut\u00f2noma de Barcelona, 08193 Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2020, June 16). Global Tuberculosis Report 2019, Available online: https:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"ref_2","unstructured":"Ministry of Health (2017). The Uganda National Tuberculosis Prevalence Survey, 2014\u20132015 Survey Report."},{"key":"ref_3","unstructured":"Ministry of Health (2017). Manual for Management and Control of Tuberculosis and Leprosy in Uganda."},{"key":"ref_4","unstructured":"Ministry of Health (2016). Uganda Clinical Guidelines 2016: National Guidelines for Management of Common Conditions."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijantimicag.2004.03.015","article-title":"Antibiotic use in German university hospitals 1998\u20132000 (Project INTERUNI-II)","volume":"24","author":"Bergner","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jac\/45.2.251","article-title":"Antibiotic use in Dutch hospitals 1991\u20131996","volume":"45","author":"Janknegt","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/jac\/dkh494","article-title":"Increase and change in pattern of hospital antimicrobial use, Denmark, 1997\u20132001","volume":"54","author":"Muscat","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.revmed.2014.05.005","article-title":"R\u00e9sistance aux fluoroquinolones en 2013: Quel impact pour l\u2019interniste?","volume":"35","author":"Fantin","year":"2014","journal-title":"Rev. Med. Interne"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/00007611-200009000-00001","article-title":"Confronting the problem of increasing antibiotic resistance","volume":"93","author":"Hellinger","year":"2000","journal-title":"South. Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kateete, D.P., Kamulegeya, R., Kigozi, E., Katabazi, F.A., Lukoye, D., Sebit, S.I., Abdi, H., Arube, P., Kasule, G.W., and Musisi, K. (2019). Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014\u20132016). BMC Pulm. Med., 19.","DOI":"10.1186\/s12890-019-0891-x"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Odongo, C.O., Anywar, D.A., Luryamamoi, K., and Odongo, P. (2013). Antibiograms from community-acquired uropathogens in Gulu, northern Uganda\u2014A cross-sectional study. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-193"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1073\/pnas.96.3.1152","article-title":"The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance","volume":"96","author":"Austin","year":"1999","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bjid.2015.09.011","article-title":"Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multi-drug resistant tuberculosis patients","volume":"20","author":"Ahmad","year":"2016","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s002280100338","article-title":"The effect of formulary restriction in the use of antibiotics in an Italian hospital","volume":"57","author":"Bassetti","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11908-018-0615-z","article-title":"Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention","volume":"20","author":"Claeys","year":"2018","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_16","unstructured":"World Health Organization (2018). WHO Report on Surveillance of Antibiotic Consumption: 2016\u20132018 Early Implementation."},{"key":"ref_17","first-page":"29","article-title":"Measurement of antibiotic consumption: A practical guide to the use of the Anatomical Thgerapeutic Chemical classification and Definied Daily Dose system methodology in Canada","volume":"15","author":"Hutchinson","year":"2004","journal-title":"Can. J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1128\/JCM.42.12.5571-5577.2004","article-title":"Trends in antimicrobial resistance in 1,968 invasive Streptococcus pneumoniae strains isolated in Spanish hospitals (2001 to 2003): Decreasing penicillin resistance in children\u2019s isolates","volume":"42","author":"Oteo","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.amjmed.2004.09.015","article-title":"Fluoroquinolone prescribing in the United States: 1995 to 2002","volume":"118","author":"Linder","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"vi47","DOI":"10.1093\/jac\/dkr457","article-title":"European Surveillance of Antimicrobial Consumption (ESAC): Outpatient quinolone use in Europe (1997\u20132009)","volume":"66","author":"Adriaenssens","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jiph.2019.03.014","article-title":"Antimicrobial consumption and bacterial resistance pattern in patients admitted in ICU at a tertiary care center","volume":"12","author":"Saxena","year":"2019","journal-title":"J. Infect. Public Health"},{"key":"ref_22","first-page":"639","article-title":"Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia","volume":"11","author":"Kabbara","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1016\/S2214-109X(19)30071-3","article-title":"Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): An analysis of paediatric survey data from 56 countries","volume":"7","author":"Hsia","year":"2019","journal-title":"Lancet Glob. Health"},{"key":"ref_24","unstructured":"Ministry of Health (2018). Annual Health Sector Performance Report Financial Year 2017\/2018."},{"key":"ref_25","unstructured":"(2020, June 16). ATC\/DDD Index 2020. Available online: https:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"ref_26","unstructured":"Royal Pharmaceutical Society (2019). British National Formulary (BNF) 78, Pramaceutil Press."},{"key":"ref_27","unstructured":"Holloway, K., and Green, T. (2003). Drug and Therapeutics Committees\u2014A Practical Guide."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/8\/439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:51:08Z","timestamp":1760176268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/8\/439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["antibiotics9080439"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9080439","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]}}}